Abstract
A major challenge in the development of a successful tumor vaccination is to break immune tolerance and to sensitize efficiently the immune system toward relevant tumor antigens, thus enabling T-cell-mediated antitumor responses in vivo. Dendritic cell (DC)-based immunotherapy shows the advantage to induce an adaptive immune response against the tumor, with the potential to generate a long-lasting immunological memory able to prevent further relapses and hopefully metastasis. Recently different preclinical studies highlighted the golden opportunity to exploit the features of immunogenic cell death (ICD) to generate ex vivo a highly immunogenic tumor cell lysate as potent antigen formulation for improved DC-based vaccine against aggressive cancers. This chapter focuses on the methods to obtain tumor lysates from cells undergoing ICD to be used for DC pulsing and to test the functionality of the generated DCs for antitumor vaccine development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P (2015) Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol 6:588. https://doi.org/10.3389/fimmu.2015.00588
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54–61. https://doi.org/10.1038/nm1523
Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G (2008) Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15(1):3–12. https://doi.org/10.1038/sj.cdd.4402269
Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, Agostinis P (2016) Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med 8(328):328–327. https://doi.org/10.1126/scitranslmed.aae0105
Montico B, Lapenta C, Ravo M, Martorelli D, Muraro E, Zeng B, Comaro E, Spada M, Donati S, Santini SM, Tarallo R, Giurato G, Rizzo F, Weisz A, Belardelli F, Dolcetti R, Dal Col J (2017) Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. Oncoimmunology 6(11):e1356964. https://doi.org/10.1080/2162402X.2017.1356964
Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P (2010) Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 1805(1):53–71. https://doi.org/10.1016/j.bbcan.2009.08.003
Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buque A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L (2014) Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3(9):e955691. https://doi.org/10.4161/21624011.2014.955691
Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169(1):350–358
Delamarre L, Couture R, Mellman I, Trombetta ES (2006) Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med 203(9):2049–2055. https://doi.org/10.1084/jem.20052442
Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES (2005) Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307(5715):1630–1634. https://doi.org/10.1126/science.1108003
Monaco JJ (1995) Pathways for the processing and presentation of antigens to T cells. J Leukoc Biol 57(4):543–547
Nencioni A, Grunebach F, Schmidt SM, Muller MR, Boy D, Patrone F, Ballestrero A, Brossart P (2008) The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 65(3):191–199. https://doi.org/10.1016/j.critrevonc.2007.10.002
Palucka AK, Ueno H, Fay J, Banchereau J (2008) Dendritic cells: a critical player in cancer therapy? J Immunother 31(9):793–805. https://doi.org/10.1097/CJI.0b013e31818403bc
Popescu I, Macedo C, Zeevi A, Nellis J, Patterson KR, Logar A, Rowe D, Reyes J, Rao AS, Storkus WJ, Fung JJ, Metes D (2003) Ex vivo priming of naive T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. Am J Transplant 3(11):1369–1377
Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R (2003) Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 171(11):5940–5947
Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G (2013) A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 19(17):4801–4815. https://doi.org/10.1158/1078-0432.CCR-13-1185
Hatfield P, Merrick AE, West E, O'Donnell D, Selby P, Vile R, Melcher AA (2008) Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother 31(7):620–632. https://doi.org/10.1097/CJI.0b013e31818213df
Kim HS, Choo YS, Koo T, Bang S, Oh TY, Wen J, Song SY (2006) Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer. Immunol Lett 103(2):142–148. https://doi.org/10.1016/j.imlet.2005.10.021
Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW (2015) Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol 6:663. https://doi.org/10.3389/fimmu.2015.00663
Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191(10):1777–1788
Lapenta C, Donati S, Spadaro F, Castaldo P, Belardelli F, Cox MC, Santini SM (2016) NK cell activation in the antitumor response induced by IFN-alpha dendritic cells loaded with apoptotic cells from follicular lymphoma patients. J Immunol 197(3):795–806. https://doi.org/10.4049/jimmunol.1600262
Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D, Franceschini D, Andreotti M, Barnaba V, Belardelli F (2006) IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol 36(8):2046–2060. https://doi.org/10.1002/eji.200535579
Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, Santini SM, Ferrantini M (2012) IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119(6):1407–1417. https://doi.org/10.1182/blood-2011-06-363564
Dauer M, Schad K, Junkmann J, Bauer C, Herten J, Kiefl R, Schnurr M, Endres S, Eigler A (2006) IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4. J Leukoc Biol 80(2):278–286. https://doi.org/10.1189/jlb.1005592
Dal Col J, Mastorci K, Fae DA, Muraro E, Martorelli D, Inghirami G, Dolcetti R (2012) Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets. Cancer Res 72(7):1825–1835. https://doi.org/10.1158/0008-5472.CAN-11-2505
Guidoboni M, Zancai P, Cariati R, Rizzo S, Dal Col J, Pavan A, Gloghini A, Spina M, Cuneo A, Pomponi F, Bononi A, Doglioni C, Maestro R, Carbone A, Boiocchi M, Dolcetti R (2005) Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res 65(2):587–595
Mastorci K, Montico B, Fae DA, Sigalotti L, Ponzoni M, Inghirami G, Dolcetti R, Dal Col J (2016) Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. Oncotarget 7(27):41913–41928. https://doi.org/10.18632/oncotarget.9630
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Nigro, A., Montico, B., Casolaro, V., Dal Col, J. (2019). A Novel Dendritic Cell-Based Vaccination Protocol to Stimulate Immunosurveillance of Aggressive Cancers. In: López-Soto, A., Folgueras, A. (eds) Cancer Immunosurveillance. Methods in Molecular Biology, vol 1884. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8885-3_22
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8885-3_22
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8884-6
Online ISBN: 978-1-4939-8885-3
eBook Packages: Springer Protocols